Cartoonist and counterculture icon R. Crumb reflects on his remarkable life and work in a new interview from his home in the South of France.

Biostatistician Jeffrey Morris discusses his analysis of the vaccine monitoring system — and how it could be improved.

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

The following is the transcript of the interview with former FDA commissioner Scott Gottlieb, who now serves on the boards of Pfizer and United Healthcare, that aired on "Face the Nation with Margaret ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump in a White House event on Tuesday. President Trump and Pfizer announced a deal to cut drug pricing yesterday. And it looks ...

President Donald Trump today, Sept. 30, announced TrumpRX, a new website for Americans to buy drugs, while he touted lower prices across Pfizer drugs, according to the Wall Street Journal. Trump ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Tony Hogben is the Immersive Studio Lead at Pfizer Digital Omnichannel Services & Solutions (OSS). Pfizer Digital Omnichannel Services & Solutions (OSS) is at the forefront of transforming how Pfizer ...

I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to ...